BioCryst Pharmaceuticals BCRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 97.8%+0.5pp | 97.3%-1.4pp | 98.6%+1.0pp | 97.6%+2.2pp | |
| Operating margin | 39%+39.5pp | -0.6%+30.7pp | -31.3%+23.5pp | -54.8%+58.3pp | |
| Net margin | 30.2%+49.9pp | -19.7%+48.6pp | -68.4%+22.9pp | -91.2%+25.9pp | |
| Efficiency | |||||
| Asset turnover | 1.7×+0.8× | 0.9×+0.3× | 0.6×+0.1× | 0.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.1×-0.6× | 2.6×-0.7× | 3.3×-1.6× | 4.9×-0.6× | |
| Leverage | |||||
| Net debt / EBITDA | -0.2×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | -$0.55+76.3% | -$2.30+2.8% | -$2.37-49.6% | -$1.58-165% | |
| Valuation | |||||
| Market capitalization | $1.64B+5.5% | $1.56B+27.0% | $1.23B-42.7% | $2.14B-14.1% | |
| Price / earnings | 6.2×— | —— | —— | —— | |
| Price / sales | 1.9×-1.6× | 3.5×-0.2× | 3.7×-4.2× | 7.9×-8.0× | |
| EV / EBITDA | 4.6×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioCryst Pharmaceuticals's profit margins?
- BioCryst Pharmaceuticals (BCRX) runs a 97.8% gross margin and a -43.1% operating margin, with a -51.7% net margin.
- Where do BioCryst Pharmaceuticals's ratios come from?
- Every ratio is computed from BioCryst Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
